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Sophie J van Asselt1,2, Elisabeth GE de Vries2, Hendrik M van Dullemen3, Adrienne H Brouwers4,
Annemiek ME Walenkamp2, Rachel H Giles5 and Thera P Links1*Abstract
Pancreatic cysts are a heterogeneous group of lesions, which can be benign or malignant. Due to improved
imaging techniques, physicians are more often confronted with pancreatic cysts. Little is known about the origin of
pancreatic cysts in general. Von Hippel-Lindau (VHL) disease is an atypical ciliopathy and inherited tumor syndrome,
caused by a mutation in the VHL tumor suppressor gene encoding the VHL protein (pVHL). VHL patients are prone
to develop cysts and neuroendocrine tumors in the pancreas in addition to several other benign and malignant
neoplasms. Remarkably, pancreatic cysts occur in approximately 70% of VHL patients, making it the only hereditary
tumor syndrome with such a discernible expression of pancreatic cysts. Cellular loss of pVHL due to biallelic
mutation can model pancreatic cystogenesis in other organisms, suggesting a causal relationship. Here, we give a
comprehensive overview of various pVHL functions, focusing on those that can potentially explain pancreatic cyst
development in VHL disease. Based on preclinical studies, cilia loss in ductal cells is probably an important early
event in pancreatic cyst development.
Keywords: Cilia, Cytoskeleton, Pancreatic cysts or serous cystadenomas, VHL tumor suppressor protein, von Hippel-
Lindau diseaseReview
Introduction
Pancreatic cysts are frequent, with a prevalence of 2.4 to
13.5% in patients without known pancreatic disease. Due
to increased use of cross-sectional imaging techniques,
physicians are more frequently confronted with pancre-
atic cysts [1]. Various types of pancreatic cysts can occur,
which can be benign or have malignant potential. An
expectative policy is accepted for benign cysts and sur-
gery is indicated for malignant lesions. Currently, accur-
ate diagnostics are not available to identify malignant
cysts [1]. Despite the need for mechanistic insight, little
is known about the origin and pathophysiology of pan-
creatic cysts in general.
Von Hippel-Lindau (VHL) disease (MIM #193300) is a
rare hereditary tumor syndrome that results from a germ-
line mutation in the VHL gene. The reported incidence is
1 per 36,000 live births and a >90% penetrance is present* Correspondence: t.p.links@umcg.nl
1Department of Endocrinology, University of Groningen, University Medical
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reproduction in any medium, provided the orby the age of 65 years [2]. VHL disease can lead to the
development of hemangioblastomas of the central ner-
vous system, retinal angiomas, endolymphatic sac tumors,
epididymis or broad ligament cystadenomas, renal cysts
and renal cell carcinomas (RCCs), pheochromocytomas,
pancreatic cysts and pancreatic neuroendocrine tumors
(pNETs) [3] (Figure 1). Currently, RCC and hemangioblas-
tomas are the main causes of death [4,5]. VHL patients
undergo screening for early detection of manifestations [6].
Understanding the role of the VHL gene in the oxygen-
sensing pathway in the tumor micro-environment of RCC
has led to major pharmaceutical successes through tar-
geted therapies for many cancer types, such as humanized
antibodies targeting vascular endothelial growth factor
(VEGF), mTOR- and VEGF receptor tyrosine kinase inhi-
bitors [7]. As a result, first-line treatment of metastasized
RCCs has entirely changed in the last decade.
pNETs are present in 10 to 17% of VHL patients [8,9]
and pancreatic cysts occur in about 70% [10,11]. Because
of this high prevalence, it is worthwhile examining the
early cellular events that result in pancreatic cysts in VHL
disease, reflecting insight into pancreatic cystic disorderstral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 VHL disease can affect various organs. On the left, the
organs in which cysts as well as solid lesions occur, have been listed
and on the right are the locations in which only hypervascular solid
lesions occur. (Constructed using Servier Medical art).
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of pVHL functions to explain cellular events involved in
cyst development in the context of VHL. Based on knock-
out mouse models, we discuss the consequences of Vhlh
loss in the pancreas and the origin of pancreatic cysts.Pancreatic involvement in VHL disease
VHL pancreatic cysts include simple cysts and serous
cystadenomas. In addition to these cysts pNETs occur in
VHL patients, which can have malignant potential [10].
One autopsy series of 50 VHL patients showed a preva-
lence of 72% for pancreatic cysts [11]. In the largest clin-
ical study describing pancreatic involvement, 158 VHLFigure 2 Axial MRI images of pancreatic involvement in three VHL pa
exocrine/endocrine insufficiency. (A) Simple cysts (arrows) with size <1 cm
cystadenoma (arrowhead) is present next to multiple simple cysts (arrows)
pancreas by multiple cysts in a 47 year old woman.patients underwent abdominal computed tomography
scan at least once. Pancreatic involvement was observed
in 77% of patients: 71% had simple cysts, 15% had serous
cystadenomas and 10% had pNETs, which coincided with
pancreatic cysts in 11 cases (69%) [10]. In VHL patients, a
broad heterogeneity is present regarding pancreatic cyst
involvement: isolated cystadenomas and small cysts occur,
whereas in some patients cystic growth replaces almost
the entire pancreas (Figure 2) [10,12-16].
Data is limited about clinical consequences of VHL
pancreatic cysts. One study [10] and numerous case-
reports [12,13,17-23] have recorded clinical problems, of
which compression of the biliary tract was most frequently
reported (Table 1). Intervention was indicated in only 3%
of VHL patients [10]. No evidence exists for an associ-
ation between endocrine or exocrine pancreatic insuffi-
ciency and cyst involvement. Moreover, no cases have
been described of malignant pancreatic cysts in VHL
disease. Nineteen cases with a pancreatic serous cystade-
noma mixed with a pNET were reported [10,14-16,24,25],
but no relationship exists between presence of pancreatic
cysts and pNETs. Conclusively, pancreatic cysts in VHL
disease are not associated with malignancy and sporadic-
ally cause problems [26].
VHL disease classification
The clearest genotype-phenotype correlation is exemplified
by type 2 VHL, typically characterized by a VHL missense
mutation and presence of pheochromocytomas [27,28].
Type 1 VHL is more frequently characterized by a VHL
truncating mutation and absence or rare occurrence of
pheochromocytomas. Type 2 VHL alleles can be fur-
ther subdivided based on absence or presence of RCC;
called VHL type 2A and type 2B, respectively [28,29].
A pheochromocytoma-only subtype has also been described:
VHL type 2C [30]. Pancreatic involvement occurs in both
VHL type 1 and type 2B, although it is unclear whether it
occurs in the rare VHL types 2A and 2C [31].tients. None of these patients had pancreas-related symptoms or
in a 32 year old man; (B) A 4 cm sized serous microcystic
in a 39 year old woman; (C) Shows replacement of almost the entire
Table 1 Complications caused by pancreatic cysts in VHL disease
Reference [No.] No. of patients Symptoms Diagnosis Therapeutic intervention
[17] 1 Jaundice Bile duct obstruction Surgery
[19] 1 Jaundice Bile duct obstruction Biliary stent
[20] 2 Jaundice Bile duct obstruction Surgery
[12] 2 Jaundice Bile duct obstruction Surgery
[22] 1 Abdominal pain, jaundice and fever Bile duct obstruction Surgery
[23] 1 Pruritis Bile duct obstruction Surgery
[10] 2 Abdominal pain Pressure/ obstruction 1 Drainage
1 Surgery
[10] 1 Not reported Necrotizing pancreatitis Expectative
[21] 1 Vomiting Pressure on stomach and duodenum Surgery
[13] 1 Abdominal swelling Hemosuccus pancreaticus Surgery
[18] 1 Abdominal swelling Duodenal compression Surgery
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The VHL gene was identified in 1993 [32] and is a tumor
suppressor gene; somatic inactivation of the wild-type allele
or loss of heterozygosity (LOH) of the VHL gene is often
observed prior to development of VHL-associated lesions
[33,34]. Consisting of three exons, the human VHL gene is
located on chromosome 3 (3p26-p25), encoding a 213-
amino acid pVHL (30 kDa VHLp30) and a 160-amino acid
shorter form (19 kDa VHLp19) [35,36]. The role of VHL in
the oxygen-sensing pathway is its best-characterized func-
tion: cellular normoxic conditions enable the pVHL E3 ubi-
quitin ligase complex to target the α-subunit of hypoxia
inducible factor (HIF) for proteosomal degradation. During
hypoxia, pVHL is not able to bind HIF-α, resulting in ac-
cumulation of un-ubiquitinated HIF-α, which then trans-
locates to the nucleus. This stimulates the transcription of
various genes, including VEGF [37].
Since pVHL is still capable of functioning within the
E3 ubiquitin ligase complex in VHL type 2C [38], other
pVHL functions must be present to induce tumorigenesis.
Indeed,VHL also regulates the assembly of the extracellu-
lar matrix (ECM) [39-45], and recent studies have shown
that pVHL regulates the microtubule cytoskeleton, par-
ticularly plus-end stability [46-54].
Sporadic pancreatic serous cystadenomas
Data suggest that VHL loss through LOH of chromosome
3p might be a common mechanism initiating cystogenesis
in sporadic pancreatic cystadenomas [55,56]. Recently,
whole-exome sequencing was performed in various spor-
adic pancreatic cysts [57]. Seven out of eight serous cysta-
denomas lost chromosome 3p alleles, and in four, VHL
gene mutations were found. This further supports that
VHL loss initiates cystogenesis in pancreatic cystadenomas.
Given that loss of the VHL locus was the only recurrent le-
sion identified, these data indicate that VHL loss alone
could be sufficient for this development. Interestingly, inthis same study, intraductal papillary mucinous neoplasms,
mucinous cystic neoplasms, and solid pseudopapillary
neoplasms did not show alterations in 3p alleles. In these
lesions other genes encoding E3 ubiquitin ligases were
involved, pointing to protein turnover as an underlying
mechanistic theme [57].
pVHL regulates cellular architecture
Most in vitro studies exploring the influence of pVHL
on the cytoskeleton have been performed in RCC cell
lines. To the best of our knowledge, no comparable stud-
ies have been performed with pancreatic cell lines. Since
somatic LOH of wild-type VHL allele has been verified in
pancreatic cysts in VHL [58], we reviewed the existing
literature based on RCC cell line studies to gain insight
into the effect of pVHL on pancreatic cell regulation and
cyst development. Figure 3 represents a schematic over-
view of pVHL functions which might also explain pancre-
atic cyst development in VHL disease.
pVHL and the extracellular matrix
The ECM consists of proteins including collagen, fibro-
nectin and laminin. Fibronectin plays a major role in the
spread and migration of cells by binding them to the
ECM. Integrins are cell surface receptors that mediate
cell-cell and cell-ECM attachment [59]. pVHL promotes
cell adhesion to the ECM [40]. VHL inactivation in RCC
cells, mouse embryos and mouse embryo fibroblasts
impair the ability to form a fibronectin assembly [39].
Fibrillar adhesions are essential to form a fibronectin
assembly. Despite sufficient fibronectin, VHL−/− RCC
cells fail to construct β1-integrin fibrillar adhesions due
to deficient integrin regulation [41]. In RCC cell lines
with wild-type VHL, collagen IV interacts with pVHL [42].
More specifically, pVHL binds the collagen IVα2 chain,
part of the triple helix collagen IV; whereas in RCC cells
with mutant pVHL this interaction fails [43]. This results
Figure 3 Schematic overview of functions of pVHL.
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eling in vivo (Figure 4) [42]. Collagen IV associates with
fibronectin, suggesting that the previously observed inter-
action between pVHL and fibronectin is indirect [43].
In a xenograft model using RCC cell lines, VHL-ECM,
VHL-HIF or both pathways were inactivated. VHL−/−
786–0 cells expressing HIF-2α failed to assemble an
ECM. VHL+/+ cells retrovirally infected to produce
proteasome-resistant HIF-2α, were still able to assemble
an ECM, indicating that it is independent of VHL-HIF
regulation. Alternatively in VHL type 2C cells, mutant
pVHL regulates HIF normally, but interferes with ECM
assembly [45]. Xenograft tumors from VHL type 2C cells
were hypervascular and invasive, similar to tumors ori-
ginating from VHL−/− 786–0 cells. In contrast, xeno-
grafts derived from VHL+/+ cells engineered to stabilize
HIF-2α resulted in tumors with lower microvessel dens-
ity and invasiveness, despite higher VEGF expression
[45]. Thus, upregulation of VEGF alone is not sufficient
for hypervascularization of tumors. Kurban et al. sug-
gested that a strong collagen IV network, dependent on
pVHL, naturally suppresses tumorigenesis [45].
pVHL and cell polarity
Epithelial cells have asymmetric specification of mem-
brane domains. Asymmetry and polarization are regulated
by partitioning defective proteins (PAR) and atypical pro-
tein kinase C (aPKC). The PAR3-PAR6-aPKC complex is
essential for establishing the apical membrane domain and
junction structures of epithelial cells [60]. In addition, this
complex is involved in formation of the apical lumen in
three-dimensional cultures [61].The pVHL ubiquitin ligase complex targets the active
form of aPKC for degradation, analogous to HIF-α [62].
VHL mutant cells fail to form intercellular junctions,
resulting in lost polarity [44]. This may be due to deregu-
lation of active aPKC. Moreover, pVHL associates with the
PAR3-PAR6-aPKC complex [50]. In a follicular epithelial
model in Drosophila, loss of wild-type vhl resulted in
epithelial disorganization, microtubule destabilization
and subsequent aPKC mislocalization [63] (Figure 4).
Duchi et al. concluded that loss of VHL in vivo can
destabilize strict planar cell polarity control, resulting in
architectural changes permissive to cyst development [63].
pVHL and microtubule dynamics
Microtubules are polymerized filaments composed of α-
and β-tubulin monomers. Microtubules continuously shrink
at their “minus-ends” and grow at their “plus-ends” [64].
pVHL promotes microtubule stabilization by reducing
tubulin turnover [46,47,54]; it binds microtubules through
kinesin-2 [48]. In vitro inhibition of tubulin GTP-ase activ-
ity by pVHL at microtubule plus-ends contributes to this
stability, which is compromised by VHL patient-associated
mutant alleles [54]. Furthermore, cellular inactivation of
pVHL results in spindle misorientation, spindle check-
point weakening and chromosomal instability attributed
to microtubule instability [53]. Interestingly, pVHL directs
growth of microtubule orientation towards the outer plasma
membrane [50].
pVHL and cilia
Microtubules form the backbone of cilia, which project
from the apical cell surface. Cilia sense outside the cell and
Figure 4 Overview of direct and indirect pVHL-regulated cell processes in an epithelial cell. The cilium (1) consists a microtubule-based
axoneme (2), and a mother (3) and a daughter centriole (4). In the cell, pVHL is located in the cilium (1), the cytoplasm (5), the endoplasmic
reticulum (6) and microtubules (7). The endoplasmic reticulum is the cellular compartment where trihelical collagen IV (8) is produced. pVHL
binds collagen IVα2 in the endoplasmic reticulum. When pVHL-collagen IVα2 binding is perturbed, defects in the collagen network results.
Integrins (9) facilitate cell-ECM (10) adhesion. Upon loss of pVHL function, misregulation of β1-integrin disturbs the fibronectin matrix assembly.
The epithelial cell polarity complex PAR3-PAR6-aPKC is located at the apical membrane (11) and LGL2 at the basolateral membrane (12).
Moreover, pVHL and PAR3-PAR6-aPKC are necessary for the formation of adherens junctions (13) and tight junctions (14). PAR3-PAR6-aPKC and
pVHL play a role in regulation of the cilium, each capable of binding kinesin-2 (15). Functional loss of pVHL destabilizes cell polarity, partially
attributable to abnormal adherens junctions [with consequent effects on the actin belt (16)] and unstable tight junctions. The relevant literature
supports a scenario whereby microtubule instability as a result of pVHL dysfunction might affect PAR3-PAR6-aPKC localization, subsequently
destabilizing cell polarity and cilia maintenance.
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of ciliary components is required for ciliary functions,
which is powered by kinesin-2. The heterotrimeric motor
kinesin-2 comprises motor subunits of kinesin superfamily
protein 3 (KIF3A, KIF3B) and kinesin-associated protein 3
(KAP3) [65]. pVHL binds KIF3A and KAP3 of kinesin-2
[48], and in the cell, mobility of pVHL is at least partially
regulated by kinesin-2 [49].In renal tissue from VHL patients, cilia are lost in cysts,
while cilia are still present in normal tissue [51]. Accord-
ingly, RCC cell lines with or without reconstitution of
wild-type VHL, show that pVHL contributes to ciliary
maintenance and stability [51,52]. Cilia loss in kidney
tubules due to pVHL dysfunction likely results from disor-
iented microtubule growth and decreased microtubule sta-
bility [50], and is associated with renal cyst development
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cysts in VHL patients are the consequence of cilia loss.
However, in a pancreatic-specific Kif3a knock-out mouse
model, cyst development was attributed to cilia loss (see
“Cilia loss in pancreatic cells in vivo”) [66]. Therefore, it is
likely that pancreatic cysts in VHL are a result of similar
consequences.
Histopathology of the pancreas in VHL
Embryonic epithelial cells that express the transcription
factor pancreatic and duodenal homeobox 1 (Pdx1) give
rise to pancreatic tissue, consisting of exocrine (acinar
and duct) and endocrine (islet) cells [67]. Centro-acinar
cells are duct cells, which connect acini with intralobular
ducts. Recently centro-acinar cells were isolated based
on specific expression of aldehyde dehydrogenase 1. In
vitro, centro-acinar cell suspensions were able to prolif-
erate with a capacity to differentiate into both exocrine
and endocrine cells [68]. Centro-acinar cells might there-
fore act as facultative progenitor cells in the mature pan-
creas for acinar, duct and islet cells (Figure 5).
Histology of pancreatic cysts and pNETs
Pancreatic cysts and pNETs in VHL disease have distinct
features. pNETs have a solid, trabecular and/or glandular
architecture with stromal collagen bands and neurosecre-
tory dense core granules [69], which are absent in VHL
pancreatic cysts [58]. Immunohistochemical staining for
chromogranin A, S-100, synaptophysin and neuron-specific
enolase showed positive expression in VHL pNETs [69].Figure 5 Pancreatic progenitor or Pdx-cells can differentiate into end
cells. Strong evidence supports the assertion that centro-acinar cells, simila
(Constructed using Servier Medical art).Pancreatic cysts stained negative for chromogranin A
and S-100 [58]. The histology of 119 pancreatic cysts
was examined in detail from nine VHL patients [58]. All
demonstrated a mixture of clear and/or amphophilic
glycogen-rich epithelial cells, endothelial cells and smooth
muscle cells. Cysts contained and were surrounded by
fibrous tissue. In both pNETs and pancreatic cysts, LOH
of VHL wild-type allele was confirmed [58,69].
The pancreas in VHL mouse models
Constitutional inactivation of Vhlh results in embryonic
lethality at 10.5 to 12.5 days of gestation, due to placental
vasculogenesis defects [70]. To investigate the develop-
ment of VHL-associated pancreatic manifestations, condi-
tional mouse models have been generated using Cre/LoxP
technology [71]. In other mouse models Vhlh, Hif-1α or
both, were conditionally inactivated in pancreatic β-cells
in order to investigate the role of pVHL in glucose metab-
olism [72-75].
In the first study [71], the Vhlh gene was inactivated in
pancreatic progenitor cells by driving Cre recombinase
with the Pdx-1 promoter. Postnatal death was observed in
the Pdx1-Cre;Vhlh f/f mice (n = 22), of which 18 were
dead within five days. Histological analyses by pathologists
blinded for genotypes showed no abnormalities. However,
five individual Pdx1-Cre;Vhlh f/f mice survived longer. At
6 to 7 months of age, no pancreatic abnormalities were
found in two Pdx1-Cre;Vhlh f/f mice. The remaining three
were sacrificed at 16 to 18 months of age. At this time
point, pancreatic tissue was replaced by fat deposition andocrine or exocrine cells, including acinar, ductal and centro-acinar
r to Pdx-cells, can differentiate into both endocrine and exocrine cells
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The epithelial lining and endothelial cells of the micro-
cystic adenomas expressed cytokeratin MAK6 and CD31,
respectively, comparable to findings of pancreatic cysts
in VHL patients [58]. In Pdx1-Cre;Vhlh f/f mice, all pan-
creatic islets were characterized by complex and dilated
hypervascularity. Some islets had a small, abnormally
shaped appearance and others were hyperplastic [71]. In
another study Pdx1-Cre;Vhlh f/f mice were born in the
normal Mendelian frequencies. At 12 months of age no
cysts or tumors were seen, but a slightly increased pan-
creatic vascularization was present, compared to control
mice [73].
In other knock-out mouse models the Vhlh gene was
inactivated by targeting endocrine pancreatic cells for
Cre recombinase [71]. In mice with conditional Vhlh in-
activation of endocrine α-cells or β-cells, no pancreatic
abnormalities were observed (n = 16). Deletion of Vhlh
alleles in α- or β-cells was confirmed by polymerase chain
reaction analysis [71]. However, others did find increased
vascularization in islets in conditional Vhlh knock-out mice
in β-cells [73-75]. Additionally, disrupted islet morphology
with α-cells scattered throughout the islets were found in
Vhlh knock-out mice in β-cells [75]. In all these models, no
pNETs were observed. Table 2 shows an overview of knock-
out mouse models, serving as aVHL pancreatic model.
Origin of pancreatic lesions in VHL
Whether pNETs originate from exocrine or endocrine
cells remains unknown [76]. In pancreatic tissue of 13
VHL patients who underwent surgery because of pNETs,
microadenomas were found ranging from 1 to 25 per
patient. Expression of cyclin D1, carbonic anhydrase 9
and HIF-1α suggests that these microadenomas occur
due to LOH of VHL in clonal lesions, which might be anTable 2 VHL (related) pancreatic knock-out mouse models
Reference [No.] Knock-out gene(s) Target cells Age (months)
[71] Vhlh Progenitor 6-8
[73] Vhlh Progenitor 12
[71] Vhlh Progenitor 16-18
[71] Vhlh Endocrine α 10-23
[71] Vhlh Endocrine β 15
[73] Vhlh Endocrine β 12
[72] Vhlh Endocrine β 6.5
[72] Vhlh; Hif-1α Endocrine β 6.5
[72] Hif-1α Endocrine β 6.5
[74] Vhlh Endocrine β N/A
[75] Vhlh Endocrine β 2
[66] Kif3a Progenitor 2
[66] Kif3a Progenitor 12early stage of pNETs. Most microadenomas were located
close to acinar cells, but were also found close to duct
or islet cells [76].
In contrast, evidence exists that pancreatic serous cysta-
denomas originate from duct cells. In these cysts and duct
cells, co-expression of cytokeratin patterns is present, as
determined immunohistochemically [77,78]. Moreover, of
38 serous cysts including two VHL-related, 70% stained
positive for mucin 6 [79], which is also expressed in duct
and essentially centro-acinar cells [80]. This suggests a
ductal/centro-acinar origin for pancreatic serous cysts [79].
Cilia loss in pancreatic cells in vivo
A study with conditionally inactivated Kif3a in pancreatic
tissue in mice suggests that pancreatic cysts originate from
duct cells, as a result of cilia loss [66]. Pdx1-Creearly;Kif3a
f/f mice were sacrificed at different time points: at two
days postnatal, loss of acini was observed and enhance-
ment of lumen between acinar cells and interstitial cells
in acini; at 15 days progressive lumen between acini and
duct dilation were found. These pathologies all pro-
gressed with age and led to acinar tissue being replaced
by adipose tissue, severe fibroses, fluid-filled cysts and
extensive ductal dilation (age 6 to 12 months). Cilia were
lacking in all pancreatic cells. To further identify the cells
of origin, conditional knock-out mice were developed for
Kif3a inactivation in islet cells only, as well as in islet and
acinar cells. In mice lacking Kif3a in islet cells, no mor-
phological abnormalities were observed. Cilia were only
present in duct and reduced in islet cells, suggesting that
pancreatic cysts originate from ductal cells [66].
Conclusions
We argue that VHL disease can serve as an excellent
model to improve the understanding of pathophysiologyPancreatic manifestations
None
Increased pancreatic vascularization








Increased vascularization in islets
Increased vascularization and α-cells scattered throughout the islets
Compromised acinar tissue
Fibrosis, ductal dilation, cysts
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role for pVHL in microtubule stabilization and subsequent
cilia maintenance. Loss of cilia is directly related to renal
cyst development in VHL and in other renal cystic syn-
dromes [51]. Other cell aspects are also involved; pVHL
influences assembly of the extracellular matrix as well as
the cytoskeleton, including cell polarity.
In Pdx1-Cre;Vhlh f/f mice with pancreatic-specific loss
of Vhlh, pancreatic cysts were observed after 16 to 18
months [71]. Conditional Kif3a knock-out in pancreatic
duct cells in mice also resulted in cysts, but changes were
already observed after 2 days [66]. Assuming that cysts
mainly result from cilia loss, these data suggest that loss
of additional alleles might be necessary for Vhlh-driven
pancreatic cyst development. In contrast, exome sequen-
cing of sporadic human pancreatic serous cysts only found
chromosome 3p loss/VHL mutations as recurrent genetic
lesions, suggesting that VHL loss is sufficient for pancre-
atic cyst development. The high prevalence of pancreatic
cysts in patients with VHL disease supports this notion.
Differences in findings might be attributed to differences
in species, since in general mice seem to be relatively re-
sistant to VHL loss when compared to humans [81], indi-
cating that in humans VHL loss alone might be sufficient
for pancreatic serous cyst development.
Monogenetic diseases like VHL provide insights which
can be translated to pancreatic cysts in general. Better
understanding and identification of genes regarding pan-
creatic cyst development will probably provide new direc-
tions for diagnostics, follow-up and treatment options.
Future studies should focus more on VHL and also other
E3 ubiquitin ligase genes, which appear to be involved in
pancreatic cysts.
Abbreviations
aPKC: Atypical protein kinase C; ECM: Extracellular matrix; HIF: Hypoxia
inducible factor; KAP: Kinesin-associated protein; LOH: Loss of heterozygosity;
PAR: Partitioning defective proteins; Pdx1: Pancreatic and duodenal
homeobox 1; pNET: Pancreatic neuroendocrine tumor; pVHL: von Hippel-
Lindau protein; RCC: Renal cell carcinoma; VEGF: Vascular endothelial growth
factor; VHL: von Hippel-Lindau.
Competing interests
The authors declare that they have no competing interests.
Authors’ contribution
SA: planning/conducting the review, collecting and analysis/interpretation of
literature, drafting the manuscript. EV: analysis/interpretation of literature,
critical review and revision of the manuscript. HD: critical review and revision
of the manuscript. AB: critical review and revision of the manuscript. AW:
critical review and revision of the manuscript. RG: analysis/interpretation of
literature, critical review and revision of the manuscript. TL: analysis/
interpretation of literature, critical review and revision of the manuscript. All
authors read and approved the final manuscript.
Acknowledgments
Supported by Grant 2008–4188 from the Dutch Cancer Society and a grant
from the VHL Family Alliance. RHG acknowledges support from EU FP7/2009
241955 “SYSCILIA”. The work was independent of the funding. We would like
to thank Esther M van Straten for assistance of illustration of Figure 4.Author details
1Department of Endocrinology, University of Groningen, University Medical
Center Groningen, PO Box 30.001, 9700 RB, Groningen, The Netherlands.
2Department of Medical Oncology, University of Groningen, University
Medical Center Groningen, PO Box 30.001, 9700 RB, Groningen, The
Netherlands. 3Department of Gastroenterology, University of Groningen,
University Medical Center Groningen, PO Box 30.001, 9700 RB, Groningen,
The Netherlands. 4Department of Nuclear Medicine and Molecular Imaging,
University of Groningen, University Medical Center Groningen, PO Box
30.001, 9700 RB, Groningen, The Netherlands. 5Department of Nephrology
and Hypertension, University Medical Center Utrecht, Utrecht, The
Netherlands.
Received: 7 December 2012 Accepted: 16 January 2013
Published: 5 February 2013References
1. de Jong K, Bruno MJ, Fockens P (2012) Epidemiology, diagnosis, and
management of cystic lesions of the pancreas. Gastroenterol Res Pract
2012:147465
2. Maher ER, Iselius L, Yates JR, Littler M, Benjamin C, Harris R, Sampson J,
Williams A, Ferguson-Smith MA, Morton N (1991) Von Hippel-Lindau
disease: a genetic study. J Med Genet 28:443–447
3. Lonser RR, Glenn GM, Walther M, Chew EY, Libutti SK, Linehan WM, Oldfield
EH (2003) von Hippel-Lindau disease. Lancet 361:2059–2067
4. Maher ER, Yates JR, Harries R, Benjamin C, Harris R, Moore AT, Ferguson-
Smith MA (1990) Clinical features and natural history of von Hippel-Lindau
disease. Q J Med 77:1151–1163
5. Neumann HP, Eggert HR, Scheremet R, Schumacher M, Mohadjer M,
Wakhloo AK, Volk B, Hettmannsperger U, Riegler P, Schollmeyer P (1992)
Central nervous system lesions in von Hippel-Lindau syndrome. J Neurol
Neurosurg Psychiatry 55:898–901
6. The VHL Handbook (2012), http://www.vhl.org/patients-caregivers/
resources/vhl-handbooks/
7. Baldewijns MM, van Vlodrop IJ, Vermeulen PB, Soetekouw PM, van Engeland
M, de Bruine AP (2010) VHL and HIF signalling in renal cell carcinogenesis. J
Pathol 221:125–138
8. Blansfield JA, Choyke L, Morita SY, Choyke PL, Pingpank JF, Alexander HR,
Seidel G, Shutack Y, Yuldasheva N, Eugeni M, Bartlett DL, Glenn GM,
Middelton L, Linehan WM, Libutti SK (2007) Clinical, genetic and
radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL)
manifested by pancreatic neuroendocrine neoplasms (PNETs). Surgery
142:814–818
9. Erlic Z, Ploeckinger U, Cascon A, Hoffmann MM, von Duecker L, Winter A,
Kammel G, Bacher J, Sullivan M, Isermann B, Fischer L, Raffel A, Knoefel WT,
Schott M, Baumann T, Schaefer O, Keck T, Baum RP, Milos I, Muresan M,
Peczkowska M, Januszewicz A, Cupisti K, Tonjes A, Fasshauer M, Langrehr J,
von Wussow P, Agaimy A, Schlimok G, Lamberts R, VHL-ICT Consortium,
German NET Registry et al (2010) Systematic comparison of sporadic and
syndromic pancreatic islet cell tumors. Endocr Relat Cancer 17:875–883
10. Hammel PR, Vilgrain V, Terris B, Penfornis A, Sauvanet A, Correas JM,
Chauveau D, Balian A, Beigelman C, O’Toole D, Bernades P, Ruszniewski P,
Richard S (2000) Pancreatic involvement in von Hippel-Lindau disease. The
Groupe Francophone d’Etude de la Maladie de von Hippel-Lindau.
Gastroenterology 119:1087–1095
11. Horton WA, Wong V, Eldridge R (1976) Von Hippel-Lindau disease: clinical
and pathological manifestations in nine families with 50 affected members.
Arch Intern Med 136:769–777
12. Cheng TY, Su CH, Shyr YM, Lui WY (1997) Management of pancreatic
lesions in von Hippel-Lindau disease. World J Surg 21:307–312
13. Kanno A, Satoh K, Hamada S, Hirota M, Masamune A, Motoi F, Egawa S,
Unno M, Ishida K, Kimura K, Shuin T, Shimosegawa T (2011) Serous cystic
neoplasms of the whole pancreas in a patient with von hippel-lindau
disease. Intern Med 50:1293–1298
14. Hough DM, Stephens DH, Johnson CD, Binkovitz LA (1994) Pancreatic
lesions in von Hippel-Lindau disease: prevalence, clinical significance, and
CT findings. AJR Am J Roentgenol 162:1091–1094
15. Mukhopadhyay B, Sahdev A, Monson JP, Besser GM, Reznek RH, Chew SL
(2002) Pancreatic lesions in von Hippel-Lindau disease. Clin Endocrinol (Oxf)
57:603–608
van Asselt et al. Cilia 2013, 2:3 Page 9 of 10
http://www.ciliajournal.com/content/2/1/316. Delman KA, Shapiro SE, Jonasch EW, Lee JE, Curley SA, Evans DB, Perrier ND
(2006) Abdominal visceral lesions in von Hippel-Lindau disease: incidence
and clinical behavior of pancreatic and adrenal lesions at a single center.
World J Surg 30:665–669
17. Beerman MH, Fromkes JJ, Carey LC, Thomas FB (1982) Pancreatic
cystadenoma in von Hippel-Lindau disease: an unusual cause of pancreatic
and common bile duct obstruction. J Clin Gastroenterol 4:537–540
18. Jackaman FR (1984) Polycystic pancreas: Lindau’s disease. J R Coll Surg
Edinb 29:121–122
19. Deboever G, Dewulf P, Maertens J (1992) Common bile duct obstruction
due to pancreatic involvement in the von Hippel-Lindau syndrome. Am J
Gastroenterol 87:1866–1868
20. Issar SK, Kumar N, Sachdeva AK, Jain P, Puri SK (1996) von Hippel-Lindau
syndrome presenting as obstructive jaundice with involvement of pancreas
in two siblings. Trop Gastroenterol 17:30–32
21. Kunzli BM, Shrikhande SV, Buchler MW, Friess H (2004) Pancreatic lesions in
von Hippel-Lindau syndrome: report of a case. Surg Today 34:626–629
22. Boujaoude J, Samaha E, Honein K, Noun R, Abboud B, Ghorra C, Sayegh R
(2007) A benign cause of obstructive jaundice with von Hippel-Lindau
disease. A case report and review of the literature. JOP 8:790–794
23. Gupta R, Chettri D, Sharma A, Duseja A, Dhiman RK, Chawla YK, Kalra N,
Gupta A, Behera A (2008) Pancreatic cysts causing biliary obstruction in von
Hippel-Lindau syndrome. JOP 9:313–316
24. Baek SY, Kang BC, Choi HY, Lee SW (2000) Pancreatic serous cystadenoma
associated with islet cell tumour. Br J Radiol 73:83–86
25. Agarwal N, Kumar S, Dass J, Arora VK, Rathi V (2009) Diffuse pancreatic
serous cystadenoma associated with neuroendocrine carcinoma: a case
report and review of literature. JOP 10:55–58
26. Charlesworth M, Verbeke CS, Falk GA, Walsh M, Smith AM, Morris-Stiff G
(2012) Pancreatic lesions in von Hippel-Lindau disease? A systematic review
and meta-synthesis of the literature. J Gastrointest Surg 16:1422–1428
27. Crossey PA, Richards FM, Foster K, Green JS, Prowse A, Latif F, Lerman MI,
Zbar B, Affara NA, Ferguson-Smith MA (1994) Identification of intragenic
mutations in the von Hippel-Lindau disease tumour suppressor gene and
correlation with disease phenotype. Hum Mol Genet 3:1303–1308
28. Chen F, Kishida T, Yao M, Hustad T, Glavac D, Dean M, Gnarra JR, Orcutt ML,
Duh FM, Glenn G (1995) Germline mutations in the von Hippel-Lindau disease
tumor suppressor gene: correlations with phenotype. Hum Mutat 5:66–75
29. Zbar B, Kishida T, Chen F, Schmidt L, Maher ER, Richards FM, Crossey PA,
Webster AR, Affara NA, Ferguson-Smith MA, Brauch H, Glavac D, Neumann
HP, Tisherman S, Mulvihill JJ, Gross DJ, Shuin T, Whaley J, Seizinger B, Kley N,
Olschwang S, Boisson C, Richard S, Lips CH, Lerman M (1996) Germline
mutations in the von Hippel-Lindau disease (VHL) gene in families from
North America, Europe, and Japan. Hum Mutat 8:348–357
30. Ritter MM, Frilling A, Crossey PA, Hoppner W, Maher ER, Mulligan L, Ponder
BA, Engelhardt D (1996) Isolated familial pheochromocytoma as a variant of
von Hippel-Lindau disease. J Clin Endocrinol Metab 81:1035–1037
31. Nordstrom-O’Brien M, van der Luijt RB, van Rooijen E, van den Ouweland AM,
Majoor-Krakauer DF, Lolkema MP, van Brussel A, Voest EE, Giles RH (2010)
Genetic analysis of von Hippel-Lindau disease. Hum Mutat 31:521–537
32. Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, Stackhouse T, Kuzmin I,
Modi W, Geil L (1993) Identification of the von Hippel-Lindau disease tumor
suppressor gene. Science 260:1317–1320
33. Maher ER, Yates JR, Ferguson-Smith MA (1990) Statistical analysis of the two
stage mutation model in von Hippel-Lindau disease, and in sporadic
cerebellar haemangioblastoma and renal cell carcinoma. J Med Genet
27:311–314
34. Crossey PA, Foster K, Richards FM, Phipps ME, Latif F, Tory K, Jones MH,
Bentley E, Kumar R, Lerman MI (1994) Molecular genetic investigations of
the mechanism of tumourigenesis in von Hippel-Lindau disease: analysis of
allele loss in VHL tumours. Hum Genet 93:53–58
35. Schoenfeld A, Davidowitz EJ, Burk RD (1998) A second major native von
Hippel-Lindau gene product, initiated from an internal translation start site,
functions as a tumor suppressor. Proc Natl Acad Sci U S A 95:8817–8822
36. Iliopoulos O, Ohh M, Kaelin WG Jr (1998) pVHL19 is a biologically active
product of the von Hippel-Lindau gene arising from internal translation
initiation. Proc Natl Acad Sci U S A 95:11661–11666
37. Haase VH (2006) The VHL/HIF oxygen-sensing pathway and its relevance to
kidney disease. Kidney Int 69:1302–1307
38. Clifford SC, Cockman ME, Smallwood AC, Mole DR, Woodward ER, Maxwell PH,
Ratcliffe PJ, Maher ER (2001) Contrasting effects on HIF-1alpha regulation bydisease-causing pVHL mutations correlate with patterns of tumourigenesis in
von Hippel-Lindau disease. Hum Mol Genet 10:1029–1038
39. Ohh M, Yauch RL, Lonergan KM, Whaley JM, Stemmer-Rachamimov AO,
Louis DN, Gavin BJ, Kley N, Kaelin WG Jr, Iliopoulos O (1998) The von
Hippel-Lindau tumor suppressor protein is required for proper assembly of
an extracellular fibronectin matrix. Mol Cell 1:959–968
40. Kamada M, Suzuki K, Kato Y, Okuda H, Shuin T (2001) von Hippel-Lindau
protein promotes the assembly of actin and vinculin and inhibits cell
motility. Cancer Res 61:4184–4189
41. Esteban-Barragan MA, Avila P, Alvarez-Tejado M, Gutierrez MD, Garcia-Pardo
A, Sanchez-Madrid F, Landazuri MO (2002) Role of the von Hippel-Lindau
tumor suppressor gene in the formation of beta1-integrin fibrillar adhesions.
Cancer Res 62:2929–2936
42. Grosfeld A, Stolze IP, Cockman ME, Pugh CW, Edelmann M, Kessler B,
Bullock AN, Ratcliffe PJ, Masson N (2007) Interaction of hydroxylated
collagen IV with the von Hippel-Lindau tumor suppressor. J Biol Chem
282:13264–13269
43. Kurban G, Duplan E, Ramlal N, Hudon V, Sado Y, Ninomiya Y, Pause A (2008)
Collagen matrix assembly is driven by the interaction of von Hippel-Lindau tumor
suppressor protein with hydroxylated collagen IV alpha 2. Oncogene 27:1004–1012
44. Calzada MJ, Esteban MA, Feijoo-Cuaresma M, Castellanos MC, Naranjo-
Suarez S, Temes E, Mendez F, Yanez-Mo M, Ohh M, Landazuri MO (2006)
von Hippel-Lindau tumor suppressor protein regulates the assembly of
intercellular junctions in renal cancer cells through hypoxia-inducible factor-
independent mechanisms. Cancer Res 66:1553–1560
45. Kurban G, Hudon V, Duplan E, Ohh M, Pause A (2006) Characterization of a
von Hippel Lindau pathway involved in extracellular matrix remodeling, cell
invasion, and angiogenesis. Cancer Res 66:1313–1319
46. Hergovich A, Lisztwan J, Barry R, Ballschmieter P, Krek W (2003) Regulation
of microtubule stability by the von Hippel-Lindau tumour suppressor
protein pVHL. Nat Cell Biol 5:64–70
47. Lolkema MP, Mehra N, Jorna AS, van Beest M, Giles RH, Voest EE (2004) The
von Hippel-Lindau tumor suppressor protein influences microtubule
dynamics at the cell periphery. Exp Cell Res 301:139–146
48. Lolkema MP, Mans DA, Snijckers CM, van Noort M, van Beest M, Voest EE,
Giles RH (2007) The von Hippel-Lindau tumour suppressor interacts with
microtubules through kinesin-2. FEBS Lett 581:4571–4576
49. Mans DA, Lolkema MP, van Beest M, Daenen LG, Voest EE, Giles RH (2008)
Mobility of the von Hippel-Lindau tumour suppressor protein is regulated
by kinesin-2. Exp Cell Res 314:1229–1236
50. Schermer B, Ghenoiu C, Bartram M, Muller RU, Kotsis F, Hohne M, Kuhn W,
Rapka M, Nitschke R, Zentgraf H, Fliegauf M, Omran H, Walz G, Benzing T
(2006) The von Hippel-Lindau tumor suppressor protein controls
ciliogenesis by orienting microtubule growth. J Cell Biol 175:547–554
51. Esteban MA, Harten SK, Tran MG, Maxwell PH (2006) Formation of primary
cilia in the renal epithelium is regulated by the von Hippel-Lindau tumor
suppressor protein. J Am Soc Nephrol 17:1801–1806
52. Lutz MS, Burk RD (2006) Primary cilium formation requires von Hippel-
Lindau gene function in renal-derived cells. Cancer Res 66:6903–6907
53. Thoma CR, Toso A, Gutbrodt KL, Reggi SP, Frew IJ, Schraml P, Hergovich A,
Moch H, Meraldi P, Krek W (2009) VHL loss causes spindle misorientation
and chromosome instability. Nat Cell Biol 11:994–1001
54. Thoma CR, Matov A, Gutbrodt KL, Hoerner CR, Smole Z, Krek W, Danuser G
(2010) Quantitative image analysis identifies pVHL as a key regulator of
microtubule dynamic instability. J Cell Biol 190:991–1003
55. Vortmeyer AO, Lubensky IA, Fogt F, Linehan WM, Khettry U, Zhuang Z (1997)
Allelic deletion and mutation of the von Hippel-Lindau (VHL) tumor suppressor
gene in pancreatic microcystic adenomas. Am J Pathol 151:951–956
56. Moore PS, Zamboni G, Brighenti A, Lissandrini D, Antonello D, Capelli P,
Rigaud G, Falconi M, Scarpa A (2001) Molecular characterization of
pancreatic serous microcystic adenomas: evidence for a tumor suppressor
gene on chromosome 10q. Am J Pathol 158:317–321
57. Wu J, Jiao Y, Dal Molin M, Maitra A, de Wilde RF, Wood LD, Eshleman JR,
Goggins MG, Wolfgang CL, Canto MI, Schulick RD, Edil BH, Choti MA, Adsay
V, Klimstra DS, Offerhaus GJ, Klein AP, Kopelovich L, Carter H, Karchin R,
Allen PJ, Schmidt CM, Naito Y, Diaz LA Jr, Kinzler KW, Papadopoulos N,
Hruban RH, Vogelstein B (2011) Whole-exome sequencing of neoplastic
cysts of the pancreas reveals recurrent mutations in components of
ubiquitin-dependent pathways. Proc Natl Acad Sci U S A 108:21188–21193
58. Mohr VH, Vortmeyer AO, Zhuang Z, Libutti SK, Walther MM, Choyke PL, Zbar
B, Linehan WM, Lubensky IA (2000) Histopathology and molecular genetics
van Asselt et al. Cilia 2013, 2:3 Page 10 of 10
http://www.ciliajournal.com/content/2/1/3of multiple cysts and microcystic (serous) adenomas of the pancreas in von
Hippel-Lindau patients. Am J Pathol 157:1615–1621
59. Cotran RS, Kumar V, Collins T (1999) Tissue repair: cellular growth, fibrosis and
wound healing. In: Cotran RS, Kumar V, Collins T (eds) Robbins pathologic basis
of disease. WB Saunders Company, Philadelphia, pp 89–112
60. Suzuki A, Ohno S (2006) The PAR-aPKC system: lessons in polarity. J Cell Sci
119:979–987
61. Martin-Belmonte F, Gassama A, Datta A, Yu W, Rescher U, Gerke V, Mostov K
(2007) PTEN-mediated apical segregation of phosphoinositides controls
epithelial morphogenesis through Cdc42. Cell 128:383–397
62. Okuda H, Saitoh K, Hirai S, Iwai K, Takaki Y, Baba M, Minato N, Ohno S, Shuin
T (2001) The von Hippel-Lindau tumor suppressor protein mediates
ubiquitination of activated atypical protein kinase C. J Biol Chem
276:43611–43617
63. Duchi S, Fagnocchi L, Cavaliere V, Hsouna A, Gargiulo G, Hsu T (2010)
Drosophila VHL tumor-suppressor gene regulates epithelial morphogenesis
by promoting microtubule and aPKC stability. Development 137:1493–1503
64. Mofrad MR, Kamm RD (2006) Introduction, with the biological basis for cell
mechanics. In: Mofrad MR, Kamm RD (eds) Cytoskeletal mechanics: models and
measurements, 1st edn. Cambridge University Press, Cambridge, pp 1–17
65. D’Angelo A, Franco B (2009) The dynamic cilium in human diseases.
Pathogenetics 2:3
66. Cano DA, Sekine S, Hebrok M (2006) Primary cilia deletion in pancreatic
epithelial cells results in cyst formation and pancreatitis. Gastroenterology
131:1856–1869
67. Pan FC, Wright C (2011) Pancreas organogenesis: from bud to plexus to
gland. Dev Dyn 240:530–565
68. Rovira M, Scott SG, Liss AS, Jensen J, Thayer SP, Leach SD (2010) Isolation
and characterization of centroacinar/terminal ductal progenitor cells in
adult mouse pancreas. Proc Natl Acad Sci U S A 107:75–80
69. Lubensky IA, Pack S, Ault D, Vortmeyer AO, Libutti SK, Choyke PL, Walther
MM, Linehan WM, Zhuang Z (1998) Multiple neuroendocrine tumors of the
pancreas in von Hippel-Lindau disease patients: histopathological and
molecular genetic analysis. Am J Pathol 153:223–231
70. Gnarra JR, Ward JM, Porter FD, Wagner JR, Devor DE, Grinberg A, Emmert-
Buck MR, Westphal H, Klausner RD, Linehan WM (1997) Defective placental
vasculogenesis causes embryonic lethality in VHL-deficient mice. Proc Natl
Acad Sci U S A 94:9102–9107
71. Shen HC, Adem A, Ylaya K, Wilson A, He M, Lorang D, Hewitt SM, Pechhold
K, Harlan DM, Lubensky IA, Schmidt LS, Linehan WM, Libutti SK (2009)
Deciphering von Hippel-Lindau (VHL/Vhl)-associated pancreatic
manifestations by inactivating Vhl in specific pancreatic cell populations.
PLoS One 4:e4897
72. Zehetner J, Danzer C, Collins S, Eckhardt K, Gerber PA, Ballschmieter P,
Galvanovskis J, Shimomura K, Ashcroft FM, Thorens B, Rorsman P, Krek W
(2008) PVHL is a regulator of glucose metabolism and insulin secretion in
pancreatic beta cells. Genes Dev 22:3135–3146
73. Cantley J, Selman C, Shukla D, Abramov AY, Forstreuter F, Esteban MA,
Claret M, Lingard SJ, Clements M, Harten SK, Asare-Anane H, Batterham RL,
Herrera PL, Persaud SJ, Duchen MR, Maxwell PH, Withers DJ (2009) Deletion
of the von Hippel-Lindau gene in pancreatic beta cells impairs glucose
homeostasis in mice. J Clin Invest 119:125–135
74. Puri S, Cano DA, Hebrok M (2009) A role for von Hippel-Lindau protein in
pancreatic beta-cell function. Diabetes 58:433–441
75. Choi D, Cai EP, Schroer SA, Wang L, Woo M (2011) Vhl is required for
normal pancreatic beta cell function and the maintenance of beta cell mass
with age in mice. Lab Invest 91:527–538
76. Perigny M, Hammel P, Corcos O, Larochelle O, Giraud S, Richard S, Sauvanet
A, Belghiti J, Ruszniewski P, Bedossa P, Couvelard A (2009) Pancreatic
endocrine microadenomatosis in patients with von Hippel-Lindau disease:
characterization by VHL/HIF pathway proteins expression. Am J Surg Pathol
33:739–748
77. Alpert LC, Truong LD, Bossart MI, Spjut HJ (1988) Microcystic adenoma
(serous cystadenoma) of the pancreas. A study of 14 cases with
immunohistochemical and electron-microscopic correlation. Am J Surg
Pathol 12:251–263
78. Egawa N, Maillet B, Schroder S, Mukai K, Kloppel G (1994) Serous oligocystic
and ill-demarcated adenoma of the pancreas: a variant of serous cystic
adenoma. Virchows Arch 424:13–17
79. Buisine MP, Devisme L, Degand P, Dieu MC, Gosselin B, Copin MC, Aubert
JP, Porchet N (2000) Developmental mucin gene expression in thegastroduodenal tract and accessory digestive glands. II. Duodenum and
liver, gallbladder, and pancreas. J Histochem Cytochem 48:1667–1676
80. Kosmahl M, Wagner J, Peters K, Sipos B, Kloppel G (2004) Serous cystic
neoplasms of the pancreas: an immunohistochemical analysis revealing
alpha-inhibin, neuron-specific enolase, and MUC6 as new markers. Am J
Surg Pathol 28:339–346
81. Hsu T (2012) Complex cellular functions of the von Hippel-Lindau tumor
suppressor gene: insights from model organisms. Oncogene 31:2247–2257
doi:10.1186/2046-2530-2-3
Cite this article as: van Asselt et al.: Pancreatic cyst development:
insights from von Hippel-Lindau disease. Cilia 2013 2:3.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
